United Kingdom-based AstraZeneca's oncology immunotherapy Imfinzi (durvalumab) has received orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of small cell lung cancer (SCLC), it was reported yesterday.
Last month, a phase three trial called CASPIAN met its primary endpoint with Imfinzi by delivering a statistically-significant and clinically-meaningful improvement in overall survival for patients suffering from extensive-stage SCLC.
The CASPIAN trial assessed Imfinzi in combination with standard-of-care etoposide and platinum-based chemotherapy against chemotherapy alone. The drug is also being assessed in limited-stage SCLC after concurrent chemoradiation therapy in a phase three trial, called ADRIATIC. Imfinzi is a human monoclonal antibody, which has been designed to target the PD-1/PD-L1 pathway.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval